Decisions made by The Danish Medicines Council in June.
Key points
-
Six new medicines were recommended.
-
Three medicines were directly placed in treatment guidelines.
-
Four medicines were not recommended as standard treatment.
Recommended as standard treatment
-
Durvalumab was recommended for resectable gastric cancer in combination with FLOT.
-
Obinutuzumab was recommended for adults with lupus nephritis for up to one year.
-
Bulevirtid was recommended for chronic hepatitis D with severe liver damage.
-
Cilta-cel was extended to patients previously treated with other BCMA-targeted medicines.
-
Glofitamab, olaparib, and sotatercept all received conditional recommendations.
Direct placements into treatment guidelines
-
Depemokimab is included directly in the treatment guideline for biological medicines for severe asthma.
-
Leuprorelin is included directly in the evidence review of medicines for medical castration in prostate cancer.
-
Somapacitan is included directly in the evidence review of medicines for growth hormone deficiency.
Not recommended as standard treatment
-
Natriumthiosulfat, givinostat, cabozantinib, and tafasitamab.
Process updates
-
Two ongoing assessments were put on hold.
-
Guidance for metastatic castration-sensitive prostate cancer and first-line unresectable NSCLC was updated after new tenders and prices.
Read more at https://medicinraadet.dk/nyheder/2026/overblik-medicinradets-beslutninger-i-juni-2026
